Marilena Vrana: The Case for Retaining Immunoglobulins on the EU Critical Medicines List
Marilena Vrana, Vice President of Public Affairs and EU Operations at Plasma Protein Therapeutics Association (PPTA), shared a post on LinkedIn:
“As discussions progress on the review of the European Medicines Agency ’s Union List of Critical Medicines, it is important to ensure that decisions remain firmly grounded in patients’ needs.
For those who depend on immunoglobulin therapies, uninterrupted access is essential.
The Union List is more than a technical exercise: it flags medicines that require particular attention from policymakers and can support efforts to strengthen the resilience and security of Europe’s medicines supply.
Read PPTA Europe’s latest statement calling for immunoglobulins to remain on the Union List of Critical Medicines, and why keeping them there matters for patients across Europe.”
Stay updated with Hemostasis Today.
-
Oct 30, 2026, 15:53Ilenia Calcaterra: Patient Blood Management Across Complex Hematological Conditions
-
Oct 30, 2026, 15:40Isabella Presch: The Practicalities of Gene Therapy Adoption in Hemophilia
-
Oct 30, 2026, 15:12Edward C.C. Wong: Navigating the Implications of the 2026 ASH Guidelines for Blood Donation
-
Oct 30, 2026, 14:53Pall T. Onundarson: Anticoagulation Guidelines Under the Influence of Pharmaceuticalisation
-
Oct 30, 2026, 14:27Isabella Presch: From Innovation to Accessibility in Cell and Gene Therapy
-
Oct 30, 2026, 14:00Abdul Mannan: A Negative PCR Does Not Exclude β-Thalassaemia
-
Oct 30, 2026, 13:53Matteo Foschi: Can Thrombolysis Safely Treat Stroke After Cardiac Procedures?
-
Oct 30, 2026, 13:42Wolfgang Miesbach: Gene Therapy-Associated Leukaemia With Clonal Persistence Over 16 Years
-
Oct 30, 2026, 12:47Louise St. Germain Bannon: Turning Thrombosis Awareness into Stroke Prevention